-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Society News
-
In Brief for May 25, 2022
5th edition of patient education book released; US FDA moves to prohibit tobacco flavoring.
-
IASLC Responds to Call for Evidence
The association strongly recommends Europe include low-dose CT in revised screening recommendations.
-
IASLC Releases Position Statement on Air Pollution on Earth Day
Association aims to bring attention to the often-overlooked links between air pollution and lung cancer.
-
IASLC’s Global Reach a Strength on the Road to a Cure for Lung Cancer
In her first letter to ICLN readers, new CEO Karen Kelly discusses keys to achieving the association’s mission.
-
Introducing the New ILCN
As we embark on a third year of practice and research during an ever-evolving, seemingly ceaseless pandemic, we know there will be more changes and challenges in store for the field of thoracic oncology. We welcome the rapid deployment of scientific advances and are grateful for how these advances have expanded our treatment options and…
-
Renowned Medical Oncologist, Investigator to Take Reins at IASLC in March
Longtime member Karen Kelly, MD, is set to become the new chief executive officer of the International Association for the Study of Lung Cancer. This March, Dr. Kelly, an internationally renowned lung cancer researcher, will begin collaborating closely with the IASLC Board of Directors and staff to achieve the goals and fulfill the mission established…
-
IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data
The IASLC has established authority as the only global multidisciplinary organization dedicated to overcoming the four major thoracic malignancies- esophageal cancer, lung cancer, mesothelioma, and thymic malignancies. As we enter the molecular age with the promise that personalized cancer treatment will improve treatment and outcomes for our patients, major barriers are arrayed before us. How…
-
IASLC Journals Share Exciting Milestones on Metrics Journeys
By Joy Curzio Posted: August 21, 2020 The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), has a 2019 impact factor of 13.357, an increase from 12.460 in 2018. Th is moves the journal’s rank to 3rd out of 64 respiratory medicine journals and…
View ILCN Archives
Provider Resources
Popular Articles